RLN1
Prorelaxin H1
Also known as: H1, REL1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P04808
- Gene
- RLN1
- Ensembl
- ENSG00000107018
- Chromosome
- 9
- Canonical length
- 185 aa
- Protein class
- Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Relaxins are known endocrine and autocrine/paracrine hormones, belonging to the insulin gene superfamily. In humans there are three non-allelic relaxin genes, RLN1, RLN2 and RLN3, where RLN1 and RLN2 share high sequence homology. The protein encoded by this gene is synthesized as a single-chain polypeptide but the active form consists of an A chain and a B chain linked by disulfide bonds. Relaxin is produced by the ovary, and targets the mammalian reproductive system to ripen the cervix, elongate the pubic symphysis and inhibit uterine contraction. It may have additional roles in enhancing sperm motility, regulating blood pressure, controlling heart rate and releasing oxytocin and vasopressin. [provided by RefSeq, Jan 2013]
Canonical amino-acid sequenceUniProt
185 residues, UniProt reviewed canonical sequence.
>P04808|RLN1
1 MPRLFLFHLL EFCLLLNQFS RAVAAKWKDD VIKLCGRELV RAQIAICGMS TWSKRSLSQE
61 DAPQTPRPVA EIVPSFINKD TETIIIMLEF IANLPPELKA ALSERQPSLP ELQQYVPALK
121 DSNLSFEEFK KLIRNRQSEA ADSNPSELKY LGLDTHSQKK RRPYVALFEK CCLIGCTKRS
181 LAKYCLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RLN1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.52
- Highest tissue expression
- 22 nTPM
Expression across tissuesHPA
Tissue
- prostate: 22 nTPM
- testis: 0.3 nTPM
- lymph node: 0.1 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
Single-cell type
- prostatic glandular cells: 19 nCPM
- fallopian tube ciliated cells: 7 nCPM
- undifferentiated spermatogonia: 3.6 nCPM
- platelets: 2.8 nCPM
- early primary spermatocytes: 2.5 nCPM
- epididymal efferent duct ciliated cells: 2.5 nCPM
Immune cell
- gdT-cell: 0.2 nTPM
- memory CD8 T-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- hypothalamus: 0.6 nTPM
- white matter: 0.5 nTPM
- cerebral cortex: 0.4 nTPM
- pons: 0.4 nTPM
- thalamus: 0.4 nTPM
- basal ganglia: 0.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.86
- gnomAD pLI
- 0.01
- gnomAD missense Z
- -1.64
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RLN1 as an antibody target. Whether an autoantibody or antibody against RLN1 could matter depends on whether native RLN1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RLN1 is annotated as secreted, so native RLN1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label RLN1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...